SecBot SecBot
425 ·Filed Oct 26, 2026

NDRA

ENDRA Life Sciences Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed1d 3h ago SEC0001477932-26-006456
Rule 425 M&A communications
Actionable Insight • Neutral

Monitor for first helium deliveries under offtake agreements and progress toward nameplate capacity in Q4 2026, which could provide revenue visibility for Renergen. The merger with ENDRA remains pending; watch for shareholder vote and regulatory approvals.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

ASP Isotopes Inc. announced that its subsidiary Renergen's Virginia Gas Project has achieved stable liquid helium production, a key operational milestone. The filing is a Rule 425 communication related to the pending merger with ENDRA Life Sciences Inc., but contains no new deal terms or financial updates for the merger itself.

Key Financial Metrics

Deal Type
merger

Key Facts

  • Tetra4, a subsidiary of Renergen, completed commissioning and achieved stable production of liquid helium at the Virginia Gas Project.
  • Liquid helium is accumulating in cryogenic storage ahead of initial deliveries under existing offtake agreements.
  • Phase 1 is expected to produce approximately 2,500 GJ/day of LNG and approximately 70 Mcf/day of liquid helium.
  • Nameplate capacity expected to be reached during Q4 2026.
  • This press release is a Rule 425 communication related to the proposed merger between ENDRA Life Sciences Inc. and ASP Isotopes Inc.

Financial Impact

No financial figures or deal value changes provided in this filing.

Risk Factors

  • Forward-looking statements regarding production ramp and offtake deliveries may not materialize as projected.
  • The merger with ENDRA is subject to stockholder approval and other closing conditions, creating execution risk.
  • Renergen's ability to obtain funding for Phase 2 of the Virginia Gas Project is uncertain.

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (Primary)0001477932-26-006456
Document: asp_425.htm0001477932-26-006456
Document: 0001477932-26-006456-index-headers.html0001477932-26-006456
Document: 0001477932-26-006456-index.html0001477932-26-006456
Document: 0001477932-26-006456.txt0001477932-26-006456
13 reports for NDRA
Performance horizon
50% Hit rate @ T+5 2 of 4 directional calls Went positive at some point 2 of 4 best @ T+60▲ +18.66%May 28, 2026
Filters
Rows
Reports for NDRA — sortable, filterable
TypeNow
Oct 26, 2026
1d ago
425
NEUTRAL ★ 3/10
$4.82awaiting T+5—$4.96 (+2.93%)
Oct 8, 2026
19d ago
3
NEUTRAL ★ 2/10
$5.46 $4.74▼ −13.19%▼ −11.22%$4.96 (−9.14%)
Oct 8, 2026
19d ago
SC 13D
BULLISH ★ 7/10
$5.46 $4.74▼ −13.19%▼ −11.22%$4.96 (−9.14%)
Oct 1, 2026
26d ago
425
MIXED ★ 6/10
$6.06 $5.46▼ −9.90%▼ −11.06%$4.96 (−18.14%)
Oct 1, 2026
26d ago
8-K
NEUTRAL ★ 4/10
$6.06 $5.46▼ −9.90%▼ −11.06%$4.96 (−18.14%)
Sep 25, 2026
4w ago
425
NEUTRAL ★ 2/10
$5.80 $6.31▲ +8.79%▲ +7.59%$4.96 (−14.47%)
Sep 9, 2026
6w ago
425
NEUTRAL ★ 2/10
$5.83 $5.13▼ −12.01%▼ −11.67%$4.96 (−14.91%)
Aug 17, 2026
10w ago
8-K
NEUTRAL ★ 5/10
$4.51 $4.75▲ +5.32%▲ +5.52%$4.96 (+10.00%)
Jul 17, 2026
14w ago
425
NEUTRAL ★ 3/10
$4.99 $5.23▲ +4.81%▲ +5.50%$4.96 (−0.58%)
Jul 9, 2026
15w ago
8-K
NEUTRAL ★ 5/10
$5.49 $5.27▼ −4.01%▼ −3.88%$4.96 (−9.64%)
Showing 10 of 13

US Market Status

Market Closed — Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 26, 2026